Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZTI-01 vs Piperacillin/Tazobactam in cUTI/AP
NCT02753946Phase 3Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of cabotegravir in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Nabriva Therapeutics plc. Primary endpoint: Overall Success (Clinical Cure and Microbiologic Eradication) at Day 19. Started Apr 2016; status: completed.
02
Drugs
cabotegravir
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT02753946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753946.